|

Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC

RECRUITINGSponsored by Instituto Nacional de Cancerologia de Mexico
Actively Recruiting
SponsorInstituto Nacional de Cancerologia de Mexico
Started2016-02
Est. completion2026-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT02734069

Summary

This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)
* Candidates for treatment with carboplatin plus paclitaxel 1st line
* Performance status (ECOG 0-2)
* Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count)
* Normal renal ultrasound prior to initiation of treatment

Exclusion Criteria:

* Patients with renal impairment (KDOQI 3-5)
* Patients who do not have computed tomography study at baseline
* Uncontrolled blood pressure (\> 140 mmHg)
* Uncontrolled diabetes (\> 130 mg / dL)
* Obstruction in kidney (s) or ureter (s)
* Dehydrated patients
* Patients with high consumption of NSAIDs (aspirin, ibuprofen, etc.\> 1 month)

Conditions4

CancerLung CancerSarcopeniaToxicity

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.